Genetically engineered mouse models of neurodegenerative diseases

Recent research has significantly advanced our understanding of the molecular mechanisms of neurodegenerative diseases, including Alzheimer's disease (AD) and motor neuron disease. Here we emphasize the use of genetically engineered mouse models that are instrumental for understanding why AD is a neuronal disease, and for validating attractive therapeutic targets. In motor neuron diseases, Cu/Zn superoxide dismutase and survival motor neuron mouse models are useful in testing disease mechanisms and therapeutic strategies for amyotrophic lateral sclerosis (ALS) and spinal motor atrophy, respectively, but the mechanisms that account for selective motor neuron loss remain uncertain. We anticipate that, in the future, therapies based on understanding disease mechanisms will be identified and tested in mouse model systems.

[1]  Iva Greenwald,et al.  Presenilin is required for activity and nuclear access of Notch in Drosophila , 1999, Nature.

[2]  Olivier Pourquié,et al.  New protease inhibitors prevent γ-secretase-mediated production of Aβ40/42 without affecting Notch cleavage , 2001, Nature Cell Biology.

[3]  Ole A. Andreassen,et al.  Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.

[4]  I. Kola,et al.  BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.

[5]  J S Beckman,et al.  Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. , 1999, Science.

[6]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[7]  B. Schrank,et al.  Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. , 2000, Human molecular genetics.

[8]  Lars Bertram,et al.  New Frontiers in Alzheimer's Disease Genetics , 2001, Neuron.

[9]  P. Lansbury.  Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Schnitzler,et al.  BACE2, a β-secretase homolog, cleaves at the β site and within the amyloid-β region of the amyloid-β precursor protein , 2000 .

[11]  M. Mesulam.  Neuroplasticity Failure in Alzheimer's Disease Bridging the Gap between Plaques and Tangles , 1999, Neuron.

[12]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[13]  A. Bernstein,et al.  Mice lacking both presenilin genes exhibit early embryonic patterning defects. , 1999, Genes & development.

[14]  D L Price,et al.  Alzheimer's disease: genetic studies and transgenic models. , 1998, Annual review of genetics.

[15]  L. Serpell,et al.  Molecular Structure of a Fibrillar Alzheimer's Aβ Fragment† , 2000 .

[16]  Anders Björklund,et al.  Prospects for new restorative and neuroprotective treatments in Parkinson's disease , 1999, Nature.

[17]  S. W. Davies,et al.  Filamentous nerve cell inclusions in neurodegenerative diseases , 1998, Current Opinion in Neurobiology.

[18]  T. Crawford,et al.  The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy , 1995, Cell.

[19]  D. Borchelt,et al.  Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  D. Price,et al.  Mutant genes in familial Alzheimer's disease and transgenic models. , 1998, Annual review of neuroscience.

[21]  L J Martin,et al.  Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. , 1999, Journal of neuropathology and experimental neurology.

[22]  J. Julien,et al.  Formation of Intermediate Filament Protein Aggregates with Disparate Effects in Two Transgenic Mouse Models Lacking the Neurofilament Light Subunit , 2000, The Journal of Neuroscience.

[23]  H. Lipp,et al.  Mice with Combined Gene Knock-Outs Reveal Essential and Partially Redundant Functions of Amyloid Precursor Protein Family Members , 2000, The Journal of Neuroscience.

[24]  Y. Jong,et al.  Treatment of spinal muscular atrophy by sodium butyrate , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  U. Monani,et al.  The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. , 2000, Human molecular genetics.

[26]  Raphael Kopan,et al.  Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1 , 2000, Nature.

[27]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[28]  R. Barbour,et al.  Purification and cloning of amyloid precursor protein β-secretase from human brain , 1999, Nature.

[29]  T. Beach,et al.  The Cholinergic Deficit Coincides with Aβ Deposition at the Earliest Histopathologic Stages of Alzheimer Disease , 2000, Journal of neuropathology and experimental neurology.

[30]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[31]  M. Albert,et al.  Alzheimer’s disease , 2000, Neurology.

[32]  P. Wong,et al.  Pathogenesis of two axonopathies does not require axonal neurofilaments , 1998, Nature.

[33]  M. Citron,et al.  Aβ-Generating Enzymes Recent Advances in β- and γ-Secretase Research , 2000, Neuron.

[34]  Joe Z Tsien,et al.  Deficient Neurogenesis in Forebrain-Specific Presenilin-1 Knockout Mice Is Associated with Reduced Clearance of Hippocampal Memory Traces , 2001, Neuron.

[35]  David G. Tew,et al.  Identification of a Novel Aspartic Protease (Asp 2) as β-Secretase , 1999, Molecular and Cellular Neuroscience.

[36]  D. Borchelt,et al.  Endoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo , 1996, Neuron.

[37]  D. Price,et al.  Presenilin 1 is required for Notch 1 and Dll1 expression in the paraxial mesoderm , 1997, Nature.

[38]  D. Borchelt,et al.  Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.

[39]  H. Cai,et al.  The Brain's Susceptibility to Amyloid Plaques , 2001, Science.

[40]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Hardy,et al.  Genetic classification of primary neurodegenerative disease. , 1998, Science.

[42]  G. Dreyfuss,et al.  The SMN–SIP1 Complex Has an Essential Role in Spliceosomal snRNP Biogenesis , 1997, Cell.

[43]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Goate,et al.  Aph-2/Nicastrin An Essential Component of γ-Secretase and Regulator of Notch Signaling and Presenilin Localization , 2002, Neuron.

[45]  D. Borchelt,et al.  An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria , 1995, Neuron.

[46]  W. Richards,et al.  Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation , 2001, Nature Neuroscience.

[47]  D. Borchelt,et al.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. , 1999, Human molecular genetics.

[48]  D. Selkoe.  Clearing the Brain's Amyloid Cobwebs , 2001, Neuron.

[49]  D L Price,et al.  Copper chaperone for superoxide dismutase is essential to activate mammalian Cu/Zn superoxide dismutase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[50]  L. WilliamsonT,et al.  神経フィラメントの欠如は,家族性筋萎縮性側索硬化症関連スーパオキジドジスムターゼ1変異に対する運動ニューロンの選択的易損性を低下させ,疾患を遅らせる , 1998 .

[51]  John Q Trojanowski,et al.  Neurodegenerative Tauopathies Human Disease and Transgenic Mouse Models , 1999, Neuron.

[52]  H. Zoghbi,et al.  Expanding Our Understanding of Polyglutamine Diseases through Mouse Models , 1999, Neuron.

[53]  L. Bruijn,et al.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. , 1998, Science.

[54]  René Hen,et al.  Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease , 2000, Cell.

[55]  H. Cai,et al.  BACE1 is the major β-secretase for generation of Aβ peptides by neurons , 2001, Nature Neuroscience.

[56]  M. Luca,et al.  Subcellular localization and axonal transport of the survival motor neuron (SMN) protein in the developing rat spinal cord. , 2000, Human molecular genetics.

[57]  Raphael Kopan,et al.  erratum: Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1 , 2000, Nature.

[58]  Jeffrey Rothstein,et al.  Mutant SOD1 causes motor neuron disease independent of copper chaperone–mediated copper loading , 2002, Nature Neuroscience.

[59]  H. Zoghbi,et al.  Polyglutamine diseases: protein cleavage and aggregation , 1999, Current Opinion in Neurobiology.

[60]  B. Sommer,et al.  Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[61]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[62]  M. Gurney,et al.  Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Alfredo G. Tomasselli,et al.  Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity , 1999, Nature.

[64]  A. F. Soleng,et al.  A thorny question: how does activity maintain dendritic spines? , 1999, Nature Neuroscience.

[65]  Hugo Vanderstichele,et al.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.

[66]  S. Younkin,et al.  The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.

[67]  Jeffrey D. Rothstein,et al.  From charcot to lou gehrig: deciphering selective motor neuron death in als , 2001, Nature Reviews Neuroscience.

[68]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[69]  J. Julien,et al.  Amyotrophic Lateral Sclerosis Unfolding the Toxicity of the Misfolded , 2001, Cell.

[70]  G. Multhaup,et al.  A Splice Variant of β-Secretase Deficient in the Amyloidogenic Processing of the Amyloid Precursor Protein* , 2001, The Journal of Biological Chemistry.

[71]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[72]  Gregory D. Longmore,et al.  γ-Secretase inhibitors repress thymocyte development , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[74]  E. Kandel,et al.  APP Processing and Synaptic Plasticity in Presenilin-1 Conditional Knockout Mice , 2001, Neuron.

[75]  Q. Zhu,et al.  Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[76]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[77]  D. Borchelt,et al.  ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions , 1997, Neuron.

[78]  Fricker,et al.  Mouse model of spinal muscular atrophy. , 2000, Drug discovery today.

[79]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[80]  G. Dawson,et al.  β-amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity , 1995, Cell.

[81]  D. Selkoe.  Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[82]  J. Tang,et al.  Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[83]  R. Nitsch,et al.  Tau Filament Formation in Transgenic Mice Expressing P301L Tau* , 2001, The Journal of Biological Chemistry.

[84]  J. Kong,et al.  Overexpression of neurofilament subunit NF-L and NF-H extends survival of a mouse model for amyotrophic lateral sclerosis , 2000, Neuroscience Letters.

[85]  Guiquan Chen,et al.  A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease , 2000, Nature.

[86]  D L Price,et al.  Genetic neurodegenerative diseases: the human illness and transgenic models. , 1998, Science.

[87]  Sangram S. Sisodia,et al.  γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in? , 2002, Nature Reviews Neuroscience.

[88]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[89]  T. Crawford,et al.  The Neurobiology of Childhood Spinal Muscular Atrophy , 1996, Neurobiology of Disease.

[90]  D. Borchelt,et al.  Corrigendum: Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin (Human Molecular Genetics (1999) 8 (397-407)) , 1999 .

[91]  M. Wolfe,et al.  A Portrait of Alzheimer Secretases--New Features and Familiar Faces , 2001, Science.

[92]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[93]  M. Pericak-Vance,et al.  The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis , 2001, Nature Genetics.

[94]  G. Koelsch,et al.  Human aspartic protease memapsin 2 cleaves the b-secretase site of b-amyloid precursor protein , 2000 .

[95]  Q. Zhu,et al.  Absence of neurofilaments reduces the selective vulnerability of motor neurons and slows disease caused by a familial amyotrophic lateral sclerosis-linked superoxide dismutase 1 mutant. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[96]  Min Xu,et al.  Photoactivated γ-secretase inhibitors directed to the active site covalently label presenilin 1 , 2000, Nature.

[97]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[98]  L. Dillon.  The Gene , 1987, Springer US.